5-异丙基-2-甲基-苯甲腈 | 40180-46-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 5-异丙基-2-甲基-苯甲腈
• 英文名称: 2-Cyan-4-isopropyl-toluol
• 英文别名: 2-Cyan-4-isopropyl-1-methyl-benzol；5-isopropyl-2-methyl-benzonitrile；2-Methyl-5-propan-2-ylbenzonitrile
• CAS: 40180-46-9
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: AXUQXIAZJAVGEU-UHFFFAOYSA-N

物化性质

• 熔点：
  43 °C
• 沸点：
  236.1±19.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-异丙基-2-甲基-苯甲腈 在 potassium carbonate 作用下， 生成 5-isopropyl-2-methyl-benzoic acid amide
  参考文献：
  名称：

  Paterno; Fileti, Gazzetta Chimica Italiana, 1875, vol. 5, p. 30

  摘要：

  DOI：
• 作为产物：
  描述：

  phosphoric acid tris-(5-isopropyl-2-methyl-phenyl ester) 、 氰化钾 生成 5-异丙基-2-甲基-苯甲腈
  参考文献：
  名称：

  Kreysler, Chemische Berichte, 1885, vol. 18, p. 1716

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] COMPOUNDS FOR TREATMENT OF GLIOBLASTOMA<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU GLIOBLASTOME
  申请人：UNIV ALBERTA

  公开号：WO2018132905A1

  公开（公告）日：2018-07-26

  The present invention relates to compounds and methods for the treatment of glioblastoma, as well as to a pharmaceutical composition comprising said compounds. More specifically the invention relates to substituted quinoline derivatives having the formula (I), (II) or (III), and a pharmaceutical composition comprising said compounds for the treatment of cancer. (Formulae (I), (II), (III))

  本发明涉及用于治疗胶质母细胞瘤的化合物和方法，以及包含该化合物的药物组合物。更具体地，本发明涉及具有化学式(I)、(II)或(III)的取代喹啉衍生物，以及包含该化合物的药物组合物，用于治疗癌症。
• [EN] SOMATOSTATIN MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE SOMATOSTATINE ET LEURS UTILISATIONS
  申请人：CRINETICS PHARMACEUTICALS INC

  公开号：WO2019157458A1

  公开（公告）日：2019-08-15

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些能够调节生长抑素的化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物，在治疗需要调节生长抑素活性的疾病、病症或疾病中使用这些化合物的方法。
• POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF
  申请人：Tulshian Deen

  公开号：US20110065738A1

  公开（公告）日：2011-03-17

  The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

  本发明涉及多环鸟嘌呤衍生物，包括多环鸟嘌呤衍生物的组合物和使用多环鸟嘌呤衍生物治疗疼痛或炎症性疾病的方法。
• GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Kats-Kagan Roman

  公开号：US20110312911A1

  公开（公告）日：2011-12-22

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  本文披露了胰高血糖素受体拮抗剂化合物。这些化合物对于治疗2型糖尿病及相关疾病非常有用。此外，还包括药物组合物和治疗方法。